Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
51 studies found for:    "Pancreatic islet cell tumors"
Show Display Options
Rank Status Study
1 Recruiting Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Islet Cell Carcinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Drug: temozolomide;   Drug: capecitabine;   Other: laboratory biomarker analysis
2 Completed Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor
Interventions: Drug: capecitabine;   Drug: cisplatin;   Drug: streptozocin;   Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: protein analysis;   Genetic: proteomic profiling;   Other: laboratory biomarker analysis
3 Recruiting Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery
Conditions: Pancreatic Alpha Cell Carcinoma;   Pancreatic Beta Islet Cell Carcinoma;   Pancreatic Delta Cell Carcinoma;   Pancreatic G-cell Carcinoma;   Recurrent Islet Cell Carcinoma
Interventions: Drug: temozolomide;   Drug: pazopanib hydrochloride
4 Recruiting Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
Conditions: Islet Cell Tumor;   Pancreatic Cancer;   Pancreatic Disease
Interventions: Other: medical chart review;   Other: survey administration;   Other: biospecimen collection
5 Unknown  Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors
Conditions: Colorectal Cancer;   Gastrointestinal Carcinoid Tumor;   Head and Neck Cancer;   Islet Cell Tumor;   Lung Cancer;   Metastatic Cancer;   Neuroendocrine Carcinoma of the Skin;   Ovarian Cancer;   Pheochromocytoma;   Sarcoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: midazolam hydrochloride;   Drug: nelfinavir mesylate;   Genetic: gene expression analysis;   Genetic: polymerase chain reaction;   Genetic: protein expression analysis;   Other: immunoenzyme technique;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Other: mass spectrometry
6 Active, not recruiting Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Metastatic Cancer
Intervention: Drug: PVA microporous hydrospheres/doxorubicin hydrochloride
7 Completed Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
Conditions: Brain and Central Nervous System Tumors;   Breast Cancer;   Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Lung Cancer;   Lymphoma;   Melanoma (Skin);   Neoplastic Syndrome
Intervention: Radiation: yttrium Y 90-edotreotide
8 Completed Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Lung Cancer;   Neoplastic Syndrome
Intervention: Drug: thalidomide
9 Unknown  Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
Conditions: Brain and Central Nervous System Tumors;   Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neuroblastoma;   Pheochromocytoma;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Radiation: yttrium Y 90-edotreotide
10 Unknown  Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neoplastic Syndrome
Interventions: Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium
11 Unknown  AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neoplastic Syndrome
Interventions: Drug: motesanib diphosphate;   Drug: octreotide acetate;   Genetic: gene expression analysis;   Genetic: protein expression analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: laboratory biomarker analysis;   Procedure: computed tomography
12 Terminated Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
Conditions: Brain and Central Nervous System Tumors;   Childhood Langerhans Cell Histiocytosis;   Gastrointestinal Carcinoid Tumor;   Head and Neck Cancer;   Intraocular Melanoma;   Islet Cell Tumor;   Kidney Cancer;   Lung Cancer;   Melanoma (Skin);   Neoplastic Syndrome;   Neuroendocrine Carcinoma of the Skin;   Pheochromocytoma
Intervention: Radiation: indium In 111 pentetreotide
13 Completed Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases
Conditions: Colorectal Cancer;   Islet Cell Tumor;   Liver Cancer;   Metastatic Cancer;   Neuroendocrine Carcinoma
Interventions: Drug: isolated perfusion;   Drug: melphalan;   Procedure: conventional surgery
14 Terminated Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
Conditions: Head and Neck Cancer;   Islet Cell Tumor;   Metastatic Cancer;   Pheochromocytoma
Interventions: Drug: octreotide acetate;   Radiation: yttrium Y 90 resin microspheres
15 Active, not recruiting Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Lung Cancer;   Neoplastic Syndrome;   Neuroendocrine Tumor
Interventions: Biological: bevacizumab;   Drug: 5-fluorouracil;   Drug: leucovorin;   Drug: oxaliplatin
16 Completed
Has Results
RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
Conditions: Neuroendocrine Carcinoma;   Islet Cell Carcinoma
Interventions: Drug: RAD001;   Drug: Octreotide Depot
17 Withdrawn Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Carcinoma
Interventions: Drug: octreotide acetate;   Drug: vatalanib;   Procedure: anti-cytokine therapy;   Procedure: antiangiogenesis therapy;   Procedure: biological  therapy;   Procedure: endocrine therapy;   Procedure: enzyme inhibitor therapy;   Procedure: growth factor antagonist therapy;   Procedure: hormone therapy;   Procedure: protein tyrosine kinase inhibitor therapy;   Procedure: somatostatin analogue therapy
18 Recruiting Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas
Conditions: Pancreatic Cyst;   Pancreatic Neoplasms;   Pancreatic Adenoma;   Pancreatic Cancer;   Pancreatic Islet Cell Tumors;   Lymph Node;   Lymphadenopathy
Interventions: Procedure: EUS-FNA;   Device: nCLE
19 Completed Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.
Conditions: Carcinoma;   Carcinoma, Renal Cell;   Neuroendocrine Tumors;   Carcinoid Tumor;   Pancreatic Islet Cell Tumors
Intervention: Other: Blood sampling by vena punction.
20 Recruiting Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Conditions: Pancreatic Cyst;   Pancreatic Neoplasms;   Pancreatic Adenoma;   Pancreatic Cancer;   Pancreatic Islet Cell Tumors;   Lymph Node;   Lymphadenopathy;   GIST
Intervention: Device: EUS-FNA: Endoscopic ultrasound fine needle aspiration: ultrasound endoscopy of a lesion with aspiration of the lesion fluid through a needle

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years